NCT05146375View on ClinicalTrials.gov

Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)

Active, not recruitingOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

November 30, 2025

Conditions
Thoracic Aortic Aneurysm
Interventions
BIOLOGICAL

TGFBR2

"TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis."

Trial Locations (1)

Unknown

Hopital Bichat-Claude Bernard, Paris

All Listed Sponsors
collaborator

Fédération Française de Cardiologie

OTHER

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

French Cardiology Society

OTHER